JMP Securities Downgrades Adamas Pharmaceuticals (ADMS) to Market Perform, Following Acquisition
Tweet Send to a Friend
JMP Securities analyst Jason N. Butler downgraded Adamas Pharmaceuticals ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
